Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.

The Journal of dermatological treatment - 1 Dec 2023

Li Qingqing

Abstract excerpt

Langerhans cell histiocytosis (LCH) is a histiocytic neoplasm characterized by a mass of CD1a + CD207 + histiocytes, exhibiting a diverse range of clinical manifestations from a self-healing rash or single bone destruction to multi-organ disease with potentially fatal consequences. The identification of MAPK signaling pathway activation, particularly BRAFV600E mutations, has propelled targeted therapy into the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histiocytosis, Langerhans-Cell
Share to Infant
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Treatment Outcome

Share to Vemurafenib

Source

Identifiers

PMID: 37941458
DOI: 10.1080/09546634.2023.2279901

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.PMID 37941458Read ↗

Refractory multisystem Langerhans cell histiocytosis in an infant: use of vemurafenib as a therapeutic option.Semantic proximity Read ↗

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.Semantic proximity Read ↗

Targeted Therapy with Vemurafenib in Brazilian Children with Refractory Langerhans Cell Histiocytosis: Two Case Reports and a Comprehensive ReviewSemantic proximity Read ↗

Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature.Semantic proximity Read ↗

Early association of Vemurafenib to standard chemotherapy in multisystemic Langerhans cell histiocytosis in a newborn: take the chance for a better outcome?Semantic proximity Read ↗

Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study.Semantic proximity Read ↗

Failure of salvage vemurafenib therapy for refractory multisystem Langerhans cell histiocytosis with BRAF-V600E mutationSemantic proximity Read ↗

Cutaneous adverse events in children treated with vemurafenib for refractory BRAFV600E mutated Langerhans cell histiocytosis.Semantic proximity Read ↗

BRAF Mutated LCH: Diagnosis and Treatment Challenges - A High-Risk Case Presentation and Discussion.Semantic proximity Read ↗

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Semantic proximity Read ↗

Vemurafenib provides a rapid and robust clinical response in paediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease based on ddPCR using cell-free circulating DNASemantic proximity Read ↗

[Updated AWMF Guideline on the Diagnosis and Treatment of Langerhans cell Histiocytosis in Children and Adolescents].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.